EUVIMEDEUVIMED entdecken
Crossref

Cardiolipin-Based Nanoparticles Inhibit α-Synuclein Fibrilization

Morgan G Stykel, Justin Medeiros, Tammy L Ryan, Shehani V Siripala, Suelen Carmago, Ping Lu, Vladimir V Bamm iD, Carla L Coackley, Scott D Ryan iD

ACS Chemical Neuroscience · 2026

DOI: 10.1021/acschemneuro.5c00688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2026. Verfasst von Morgan G Stykel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Biology, The University of Guelph, Guelph, ON N1G 2W1, Canada. Hauptthemen laut MEDLINE: alpha-Synuclein, Nanoparticles, Cardiolipins, Synucleinopathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synucleinopathies are a group of neurodegenerative disorders characterized by structural aberrations in the protein alpha-synuclein (α-syn). In these disorders, α-syn accumulates and misfolds, contributing to the formation of intracellular inclusion bodies believed to precede cellular death. We investigated the capacity of cardiolipin (CL)-based nanoparticles to reverse α-syn fibrillization, and rescue loss of dopamine neurons. Using circular dichroism (CD) and transmission electron microscopy (TEM), we assessed conformational changes in α-syn upon interaction with CL-nanoparticles. Combined with functional assessment of CL-nanoparticles in rodent models of synucleinopathy, we demonstrate that CL nanoparticles induced structural refolding of fibrillar α-syn toward a monomeric α-helical form, dissolving α-syn aggregates and rescuing from cell death. Thus, CL-based nanoparticles may represent a therapeutic tool to mitigate synucleinopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinNanoparticlesCardiolipinsSynucleinopathiesAnimalsHumansDopaminergic NeuronsRatsMice

Stichwörter der Autor:innen

alpha-synuclein (α-synuclein)cardiolipinlipid nanoparticlesneuronprotein structure

Substanzen

alpha-SynucleinCardiolipins

Autor:innen und Institutionen

  • Department of Molecular and Cellular Biology, The University of Guelph, Guelph, ON N1G 2W1, Canada.
  • Department of Cardiac Sciences, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • Department of Clinical Neuroscience, University of Calgary, Calgary, AB T2N 4N1, Canada.
  • Department of Physiology and Pharmacology, University of Calgary, Calgary, AB T2N 4N1, Canada.

ORCID-Profile: Vladimir V Bamm, Scott D Ryan

Förderung

  • Canadian Institutes of Health Research
  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Stykel, M. G., Medeiros, J., Ryan, T. L., Siripala, S. V., Carmago, S., Lu, P., Bamm, V. V., Coackley, C. L., & Ryan, S. D. (2026). Cardiolipin-Based Nanoparticles Inhibit α-Synuclein Fibrilization. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00688

Vancouver

Stykel MG, Medeiros J, Ryan TL, Siripala SV, Carmago S, Lu P, et al. Cardiolipin-Based Nanoparticles Inhibit α-Synuclein Fibrilization. ACS Chemical Neuroscience. 2026. doi:10.1021/acschemneuro.5c00688

BibTeX
@article{Stykel2026,
  author = {Stykel, Morgan G and Medeiros, Justin and Ryan, Tammy L and Siripala, Shehani V and Carmago, Suelen and Lu, Ping and Bamm, Vladimir V and Coackley, Carla L and Ryan, Scott D},
  title = {Cardiolipin-Based Nanoparticles Inhibit α-Synuclein Fibrilization},
  journal = {ACS Chemical Neuroscience},
  year = {2026},
  doi = {10.1021/acschemneuro.5c00688}
}
Kostenlos starten →